Nanovaccine-based strategies for lymph node targeted delivery and imaging in tumor immunotherapy

Table 3 Representative polymer-based nanovaccines for targeting LNs in tumor immunotherapy

Class of nanovaccines	Size of nanovaccines	Zeta potential of nanovaccines	Active components	Mechanism of targeting LNs	Anti-tumor effects	Refs.
HMs	22.6 ± 1.15 nm	Negative charge: 31.40 ± 1.37 mV	Trp2, CpG OND	Tailoring the physicochemical composition	Expanded antigen specific cytotoxic T lymphocytes; Inhibited tumor growth in lung metastatic melanoma model	[108]
nanoSTING-vax	20–100 nm	Neutral charge	cGAMP, OVA-derived peptide SGLEQLESIINFEKL, PEG-DBP	Proton sponge effect; Embedding of sensitive bonds	Complete tumor rejection; Durable antitumor immune memory	[109]
PDs/OVA	70.27 ± 0.51 nm	Positive charge: 37.98 ± 0.60 mV	PAA-PEI600, OVA	Proton sponge effect; Embedding of sensitive bonds	Inhibited tumor growth of the mice bearing E.G7-OVA tumor and prolonged their survival time	[110]
Man-CTS-TCL NPs	120 nm	Negative charge: − 12 mV	Mannose, tumor cell lysates	Targeted ligand modification	Enhanced cytotoxic T lymphocytes responses against tumor; Significantly delayed tumor growth in mice	[111]

ISSN: 1477-3155